A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort

Freedom from disease activity in multiple sclerosis

(2015) E. Havrdova et al.   NEUROLOGY

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

(2013) Tomas Olsson et al.   Multiple Sclerosis Journal

Immunological Markers of Optimal Response to Natalizumab in Multiple Sclerosis

(2012) Luisa M. Villar   ARCHIVES OF NEUROLOGY

Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy

(2012) Olivier Outteryck et al.   JOURNAL OF NEUROLOGY

Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis

(2012) Luca Prosperini et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Humoral immune response to influenza vaccine in natalizumab-treated MS patients

(2012) Mattias Vågberg et al.   NEUROLOGICAL RESEARCH

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

(2012) A. K. Trampe et al.   NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1

(2011) Carmen Bozic et al.   ANNALS OF NEUROLOGY

Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity

(2011) David Bates et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients

(2011) Felipe von Glehn et al.   Multiple Sclerosis Journal

The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study

(2010) Oscar Fernández et al.   Multiple Sclerosis Journal

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

(2010) Fredrik Piehl et al.   NEUROLOGICAL SCIENCES

Three years of experience: the Italian registry and safety data update

(2010) G. L. Mancardi et al.   NEUROLOGICAL SCIENCES

B-cell subsets up-regulate α4 integrin and accumulate in the cerebrospinal fluid in clinically isolated syndrome suggestive of multiple sclerosis onset

(2010) Catalina Lee-Chang et al.   NEUROSCIENCE LETTERS

Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors

(2009) Adrian Egli et al.   JOURNAL OF INFECTIOUS DISEASES

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

(2009) M. Hutchinson et al.   JOURNAL OF NEUROLOGY

Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice

(2009) Olivier Outteryck et al.   JOURNAL OF NEUROLOGY

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

(2009) J. Mellergård et al.   Multiple Sclerosis Journal

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis

(2008) M. Krumbholz et al.   NEUROLOGY